Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Dawn Svoronos to be replaced by Frank Holler (MPC)

<< Previous

Bullboard Posts

Next >>

Post by Saurus100on Apr 15, 2024 10:29am

167 Views

Post# 35989246

Dawn Svoronos to be replaced by Frank Holler (MPC)

In the Management Proxy Circular (page 9) "The Board has agreed that Mr. Frank Holler, a current director and the current Chair of the Audit Committee, would be appointed as Chair of the Board in replacement of Ms. Dawn Svoronos after the Meeting if he is elected as a director of the Corporation"

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec